Annual financial performance disclosures for Karyopharm Therapeutics indicate that total annual revenues hover between one hundred and thirty million and one hundred and fifty million United States dollars. This top-line figure is generated primarily through U.S. net product sales of its commercial oncology drug XPOVIO, supplemented by international licensing royalties, milestone payments, and strategic partnership agreements established with global pharmaceutical collaborators.